CNXU — Conexeu Sciences Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 2066836 ·
Last close
$2.00
Market Cap
$56.41M
52W High
$18.79
52W Low
$1.93
ADV30
333,396
Next earnings
2027-01-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -7,689,014 | -7,725,651 | 7,156,074 | 1,971,408 | 1,305,684 |
| Apr 2026 | 0 | — | -2,376,724 | -2,304,283 | 8,199,679 | 6,848,064 | 1,003,296 |
| Jan 2026 | 0 | — | -1,720,927 | -1,718,823 | 7,702,677 | 6,255,388 | 876,275 |
| Oct 2025 | 0 | — | -1,873,405 | -1,876,873 | 7,688,711 | 4,808,965 | 336,018 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,530,844
Investing CF
$-107,171
Financing CF
$12,011,002
CapEx
$-76,629
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.54
As of
2026-09-20
Balance + Analyst (yfinance extras)
Retained Earnings
$-16,270,277
Inventory
—
Receivables
$2,426
ST Investments
—
EBIT TTM
$-13,625,630
Pretax Income TTM
$-13,625,630
Interest Exp TTM
$0
Analysts
1
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -3,958,329 | -3,923,557 | 7,688,711 | 336,018 | 7,352,693 | -1,669,975 |
| Oct 2024 | 0 | -643,042 | -471,867 | 533,940 | 438,976 | 94,964 | -225,439 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$7,156,074
Forward EPS
$-0.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| POSC | POSITRON CORP | $55.84M | $1.70 | — |
| MDNC | Medinotec Inc. | $58.78M | $5.00 | — |
| OM | Outset Medical, Inc. | $59.64M | $3.16 | — |
| COCH | Envoy Medical, Inc. | $53.20M | $6.87 | — |
| AURX | Nuo Therapeutics, Inc. | $52.79M | $1.09 | — |
News headlines (Yahoo Finance, 1h cache)
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
2026-11-19 13:30 · Yahoo
Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform
2026-11-17 13:30 · Yahoo
Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration
2026-11-10 13:30 · Yahoo
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
2026-10-15 20:30 · Yahoo
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
2026-09-01 15:37 · Yahoo
Conexeu Sciences Sets September and October 2026 Conference Schedule
2026-09-01 12:30 · Yahoo
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
2026-08-11 12:30 · Yahoo
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
2026-07-14 12:30 · Yahoo
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
2026-06-25 12:30 · Yahoo
Is Conexeu Sciences (CNXU) Quietly Redefining Its Commercial Ambitions With CXU Platform Moves?
2026-06-19 06:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.